Connective Tissue Oncology Society Annual Meeting | Conference

Novel Agent Fails to Show Sufficient Activity in Recurrent Osteosarcoma
November 14, 2017

The GPNMB-targeted agent known as glembatumumab vedotin was reasonably well tolerated and showed some activity in a phase II study of recurrent/refractory osteosarcoma, but this activity was not enough to continue the drug’s evaluation in this setting based on the study protocol.

Aftercare in Sarcoma Should Incorporate Time- and Risk-Adjusted Strategies
November 12, 2017

An analysis of more than 800 patients found that the one-size-fits-all approach to “aftercare” for localized soft-tissue sarcoma is misguided. Local recurrence and distant metastasis occur in a non-constant fashion in the years after treatment, and a time- and risk-adapted strategy for aftercare is warranted.

Regional Hyperthermia Plus Chemo Improves Outcomes in Soft-Tissue Sarcoma
November 11, 2017

Treatment with hyperthermia improved survival when added to neoadjuvant chemotherapy for patients with localized high-risk soft-tissue sarcoma.

Lurbinectedin Effective in Early Trial of Advanced Ewing Sarcoma
November 11, 2017

Lurbinectedin demonstrated clear antitumor activity as a single agent in patients with advanced or relapsed Ewing sarcoma, according to results of a phase II trial.

Cabozantinib Shows Early Promise in Soft-Tissue Sarcoma
November 10, 2017

The first phase II study of cabozantinib in soft-tissue sarcoma yielded several responses, including several subtypes such as alveolar soft-part sarcoma and myxoid liposarcoma.

Combined Immunotherapy Shows Promise in Certain Sarcoma Subtypes
November 10, 2017

The combination of durvalumab and tremelimumab offered a modest response rate in unselected patients with heavily pretreated metastatic sarcoma, but higher rates were seen in specific subtypes, including angiosarcoma and alveolar soft-part sarcoma.

T-Cell Therapy With Fludarabine Active in Synovial Sarcoma
November 10, 2017

NY-ESO-1 SPEAR T-cell therapy showed promising results and was reasonably safe in patients with synovial sarcoma, according to a new study. The addition of fludarabine may be important to achieving those positive results.

Isolated Limb Perfusion for Advanced Angiosarcoma Offers High Limb Salvation Rate
November 09, 2017

Isolated limb perfusion with high-dose melphalan and TNF-alpha has a high response rate and results in good survival outcomes in patients with locally advanced angiosarcoma, according to results of a new study.

Axitinib/Pembrolizumab Shows Promising Results in Alveolar Soft-Part Sarcoma
November 09, 2017

The combination of axitinib and pembrolizumab was reasonably well tolerated and showed promising activity in patients with various subtypes of soft-tissue sarcoma, with the benefit seen primarily in those with alveolar soft-part sarcoma, according to a new study.

Tazemetostat Is Active, Well Tolerated in Rare Epithelioid Sarcoma
November 09, 2017

The EZH2 inhibitor tazemetostat has shown good activity and is very well tolerated in an analysis of three trials of patients with the rare sarcoma subtype known as epithelioid sarcoma.